A Single-Arm, Open-Label, Multicenter Phase Ii Study Of Camrelizumab In Patients With Recurrent Or Metastatic (R/M) Nasopharyngeal Carcinoma (Npc) Who Had Progressed On Theta 2 Lines Of Chemotherapy: Captain Study
ANNALS OF ONCOLOGY(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要